Efficacy of Carbopol 974P (Siccafluid) in the treatment of severe to moderate keratoconjunctivitis sicca (KCS) in patients with primary Sjögren’s syndrome (SS) not responding to standard treatment with artificial tears

Ostuni, Pierantonio; Battista, M E C; Furlan, Antonio

doi:10.4081/reumatismo.2005.119

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 C-57BL/6 mice were equally divided into five groups i) control; ii) ERL; iii) ERL plus control vehicle; iv) ERL plus PES_103 0.1%; v) ERL plus commercially available artificial tears (Carbopol974 -Trade Name SiccaFluid ® ) [31,32]. The eyes of each group were selected so as to avoid both eyes of a mouse being assigned to the same treatment group, with the only exception of the control group.…”

mentioning

confidence: 99%

A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome

Mori

Lorenzo

Torre

et al. 2012

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Dry eye syndrome (DES) or keratoconjunctivitis sicca is an eye disease caused by the chronic lack of lubrication and moisture of the eye. The pathogenesis of DES involves the over-expression and over-activity of corneal Matrix Metalloproteinase 9 (MMP-9). We propose herein a new, non-symptomatic approach for the treatment of DES based on the inhibition of MMP-9 by a new highly soluble molecule, designed as PES_103 that has been shown to inhibit MMP-9 both in vitro and in vivo. The efficacy of PES_103 in vivo and the potential benefits of this treatment in restoring tear production were studied in this work using an animal model of reduced lacrimation. PES_103 did not show any significant corneal toxicity.Matrix metalloproteinases (MMPs) are a family of zinc containing hydrolases with a broad proteolytic specificity and large structural similarity [1]. These enzymes are involved in the degradation of several extracellular proteins including extracellular matrix components (ECM) and play a crucial role in tissue remodelling and in the regulation of different cellular activities [2]. An aberrant MMPs activity often promotes an excessive degradation of the ECM and could be responsible for the genesis of diseases such as inflammation, angiogenesis and cancer [3]. Recently, relevant ocular disorders such as proliferative diabetic retinopathy and dry eye syndrome (DES), or keratoconjunctivis sicca, have been associated with a significant increase in the concentration and activity of MMPs in the tear fluid [4-6]. In particular, DES has been associated with the over-expression and increased activity of corneal Matrix Metalloproteinase-9 (MMP-9 or Gelatinase B) [7], which has been shown to be both a marker and a promoter of eye dryness [8]. According to the work of Pflugfelder et al. [9], MMP-9 knockout mice do not develop DES, whereas the topical administration of active MMP-9 to such mice significantly increased corneal epithelial permeability.The 2007 Report of the Dry Eye WorkShop (DEWS) defined dry eye as an eye disease that results mostly in symptoms of discomfort, visual disturbance and tear film instability, with potential damage to the ocular surface that affects about 20% of the American population and 75% of the over-65-year population [10,11]. DES can be caused by a decrease in tear production or an increase in tear film evaporation, hence being represented by reduced lacrimation models. Persistent dryness, burning and a sandy-gritty eye irritation are the most common symptoms associated with DES and, in general, get worse as the day goes on [12]. Generally, both eyes are affected by DES and the physical damage occurs mainly at the corneal level. The aetiology of this syndrome is manifold, from the normal ageing process, to the effects of different drugs [13], to climatic factors together with daily routines and working-related features, such as standing in front of a computer screen, the use of air conditioning or of contact lenses [14,15]. DES is even a symptom of many systemic diseases. In particu...

show abstract

mentioning

confidence: 99%

A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome

Mori

Lorenzo

Torre

et al. 2012

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Furthermore, gargling not only aids in lubrication but also diminishes oral complications such as oral ulcers and dental caries. [31][32][33] 4.2.3.2. Immunosuppressant.…”

Section: First Authormentioning

confidence: 99%

Primary Sjogren syndrome – A bibliometric analysis via CiteSpace

Yang,

Wang,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

This study employs CiteSpace software to analyze the research status, hotspots, and trends of primary Sjogren syndrome (pSS). Relevant publications from 1999 to 2023 were searched in the Web of Science Core Collection (WoSCC) set, followed by generating a network map using CiteSpace software to identify top authors, institutions, countries, keywords, journals, references, and research trends. A total of 3564 valid articles were included in this study. The People Republic of China had the highest number of articles (n = 524), while the University of Bergen emerged as the institution with the highest publication count (n = 94). Mariette X was identified as the author with the most publications (n = 67), whereas Vitali C received recognition as the most cited author (n = 1706). Annals of Rheumatic Diseases stood out as the journal with the highest citation count (n = 2530). Notably, an article published in the Annals of Rheumatic Diseases in 2017 garnered significant attention by being cited a remarkable 304 times. The bibliometric analysis reveals that key areas of research in pSS encompass investigating pathogenesis; advancing and applying targeted biological agents; and establishing treatment and diagnostic standards.

show abstract

Efficacy of Carbopol 974P (Siccafluid) in the treatment of severe to moderate keratoconjunctivitis sicca (KCS) in patients with primary Sjögren’s syndrome (SS) not responding to standard treatment with artificial tears

Cited by 2 publications

References 9 publications

A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome

A Highly Soluble Matrix Metalloproteinase‐9 Inhibitor for Potential Treatment of Dry Eye Syndrome

Primary Sjogren syndrome – A bibliometric analysis via CiteSpace

Contact Info

Product

Resources

About